Carl D. Regillo, MD, FACS, FASRS

Articles

Considerations for the Future of Biosimilars in the Treatment of Retinal Disorders

Carl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.

Practical Implications of Increased Utilization of Biosimilars in Practice

Carl D. Regillo, MD, and Jennifer I. Lim, MD, talk about the potential cost savings as well as other real-world implications associated with the use of biosimilars in clinical practice.

Biosimilar Indications and Routes of Administration

Carl D. Regillo, MD, and Jennifer I. Lim, MD, caution against the ophthalmic use of biosimilar products approved for systemic use. They also review how indications for biosimilars are granted upon approval.